PeptideLabs Logo
PeptideLabs
All profiles

Melanotan II

Peptide · Melanocortin

Influences pigmentation and other melanocortin signals; safety and purity of unapproved products are uncertain.

Not FDA/EMA approved
LibraryNo account · this device only

Also known as: MT-2 · MT-II · MT-2 Melanotan 2 Acetate · Melanotin Receptor Type 2 · Synthetic melanocortin peptide

Use at a glance

Melanotan II

Influences pigmentation and other melanocortin signals; safety and purity of unapproved products are uncertain.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
100–250 µg
How often?
once per day
What time of day?
evening
What period?
Day 1–3
How is it used?
Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?
No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.
View preparationCheck sources
Overview of all entries

  • Melanotan II · Day 1–3

    Online report · not medically verified

    100–250 µg · once per day · evening

  • Melanotan II · Day 4–14

    Online report · not medically verified

    250–500 µg · once per day · evening

  • Melanotan II · Week 3–6

    Online report · not medically verified

    500–1,000 µg · once per day · evening

  • Melanotan II · maintenance reports

    Online report · not medically verified

    250–1,000 µg · 1–2 times per week · not reliably established

More factsPeptide · Melanocortin
Classification
Peptide · Melanocortin
Research focus
Influences pigmentation and other melanocortin signals; safety and purity of unapproved products are uncertain.
Evidence
Anecdotal
Status
Not FDA/EMA approved

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Schedule explained in detailCommunity/research information only

Amount status

Community source: days 1–3, 100–250 µg daily; days 4–14, 250–500 µg; weeks 3–6, 500–1,000 µg; maintenance 250–1,000 µg once or twice weekly. Not a recommendation. TGA testing found identically labelled 30 mg products actually contained roughly 22–54 mg.

Profile evidence level: anecdotal.

Timing

Often mentioned online in the evening because of nausea; UV timing is not validated, and tanning does not protect against UV damage.

No individual recommendation.

Cycle/duration

Community loading phase up to six weeks, then irregular maintenance. Product variability makes any seemingly precise plan uncalculable.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

10 mg · assumed final volume: 2 ml

Community calculation example
Calculated amount250 µg
Concentration5,000 µg/ml
U-1005 U
Volume0.05 ml
Calculated amount500 µg
Concentration5,000 µg/ml
U-10010 U
Volume0.1 ml
Calculated amount1,000 µg
Concentration5,000 µg/ml
U-10020 U
Volume0.2 ml

10 mg · assumed final volume: 1 ml

Community calculation example
Calculated amount500 µg
Concentration10,000 µg/ml
U-1005 U
Volume0.05 ml
All preparation informationProduct details and calculation examples from the available sources.

Community arithmetic assuming the label figure alone at 10 mg +2 ml: 250 µg =5 U, 500 µg =10 U, 1 mg =20 U. Because of documented mis- and variable dosing, even this mathematically correct calculation is not a reliable content determination.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Non-selective melanocortin receptor agonist

Melanotan II is classified as “Non-selective melanocortin receptor agonist”. Influences pigmentation and other melanocortin signals; safety and purity of unapproved products are uncertain. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Non-selective melanocortin action

This studies how a substance engages several melanocortin receptor subtypes at once rather than just one, potentially causing broader but less predictable effects, comparable to a master key rather than a single key. Various body responses are measured in parallel in studies.

02

Melanocortin receptor activation

This studies how activating melanocortin receptors affects pigmentation or sexual arousal signals, like a switch controlling different body functions depending on the receptor subtype. Skin pigmentation or physiological arousal markers are measured in studies.

03

Pigmentation and light response

This studies how skin pigment cells respond to signals that darken skin, potentially reducing sensitivity to sunlight, similar to how a photograph darkens with more exposure. Researchers typically measure skin pigment levels and light sensitivity in study participants.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Cosmetic procedure forums

Users compare tanning or skin changes after using melanocortin-related substances, often based on shared photos rather than medical examination. Such posts do not establish reviewed safety, especially for unapproved variants.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Vendor marketing claims

Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.

Adverse effects and safety risks

  • Melanocortin activity can cause nausea, flushing, blood-pressure changes, headache, unwanted pigmentation and sexual adverse effects; non-selective analogues add uncertainty.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Atypical moles/skin-cancer risk, uncontrolled blood pressure, cardiovascular disease, priapism risk and pregnancy require medical assessment.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on the approved use, skin examination, blood pressure, nausea, pigment changes and indication-specific endpoints may be assessed.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Anecdotal

Safety and purity of unapproved products are uncertain, and robust human data are lacking.

Clinical evidence

Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.

Melanotan II is a non-selective, unapproved precursor from which the approved agents afamelanotide and bremelanotide were developed.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile